Abstract:Malignant gliomas are the most common (60–70%) of all CNS/brain tumors. Annually, thereare approximately five cases of malignant gliomas per 100,000 people, and over 14,000 newcases are diagnosed each year in the United States (1,2). Surgery remains the standard therapyfor primary brain tumors. Although surgery may be combined with radiation therapy and/orfollowed with chemotherapy to destroy remaining cancer cells, patients still have a poorsurvival (3-5). In recent years, Temozolomide (TMZ, Temodar®), a prodrug which undergoesspontaneous conversion to the active alkylating agent (Charts 1 and 2) has emerged as a potentchemotherapeutic agent (6). In combination with radiotherapy, it has been shown tosubstantially increase median survival compared with radiotherapy alone (7). However, TMZhas considerable toxicity, which prevents therapeutic dosage increase. Moreover, anotherlimiting factor of TMZ treatment is tumor resistance to the drug (8-10).Recently, efforts have been made to develop delivery systems for conventionalchemotherapeutic drugs. Polymer-based delivery systems are less immunogenic than proteinbased,e.g. viral vectors, and allow repetitive treatments without acute or chronic host immuneresponse (11-14). Compared with most chemotherapeutic molecules, macromolecules offerseveral advantages, including tumor targeting, increased solubility, enhanced accumulation insolid tumors, decreased general toxicity, increased maximum tolerated doses, circumventionof multidrug resistance and enhanced apoptosis induction (15,16). Nanodrugs can selectivelyaccumulate in tumor through a passive targeting mechanism known as enhanced permeabilityand retention (EPR) effect (17-19). Targeting efficiency is substantially enhanced bycombining nanodrugs with specific antibodies that allow targeting by binding to antigens onthe tumor cell surface (20-22).To avoid systemic side effects by orally administered TMZ, targeting to brain tumor would behighly important. Recently, Brem (23) and Akbar (24) have administered a solid mixture ofbiodegradable polymer and TMZ directly into the brain tumor in animal models. The drug wasprogressively released during degradation of the embedding polymer material and significantlyprolonged the survival time of experimental animals. These methods are invasive, and the drugis applied at the time of surgery. Moreover, gliomas are tumors with the ability to developrecurrences; thus, systemic and targeted delivery of TMZ would be a more beneficial treatmentapproach.Following I.V. administration, we have delivered antisense oligonucleotides specifically tobrain tumor using the targeted nanoconjugate delivery system, Polycefin (21). Thenanoconjugate platform, poly(β-L-malic acid) (PMLA), is biodegradable, non-toxic and nonimmunogenic,containing numerous pendant carboxyl groups suitable for the covalentattachment of prodrugs and other useful molecules. For the delivery into the cytoplasm ofrecipient glioma cells, we conjugated TMZ in its hydrazide form with PMLA along with antitransferrinreceptor (TfR) monoclonal antibody (mAb) for tumor targeting by receptormediatedendocytosis (21) and pH-sensitive trileucine (LLL) for disruption of endosomalmembranes.

Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide

Rational Design of Pectin–Chitosan Polyelectrolyte Nanoparticles for Enhanced Temozolomide Delivery in Brain Tumor Therapy

Development and characterization of temozolomide-PAMAM-siRNA dendriplexes for the effective management of glioblastoma multiforme

Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(β-L-malic acid)

Quality-by-design-engineered mitochondrial targeted nanoparticles for glioblastoma therapy

Polymer-Drug Conjugates Codeliver a Temozolomide Intermediate and Nitric Oxide for Enhanced Chemotherapy Against Glioblastoma Multiforme

Preparation of transferrin-targeted temozolomide nano-micelles and their anti-glioma effect

Angiopep-2 Grafted PAMAM Dendrimers for the Targeted Delivery of Temozolomide: In Vitro and In Vivo Effects of PEGylation in the Management of Glioblastoma Multiforme

Temozolomide Conjugated Carbon Quantum Dots Embedded in Core/Shell Nanofibers Prepared by Coaxial Electrospinning as an Implantable Delivery System for Cell Imaging and Sustained Drug Release

Polydopamine-based loaded temozolomide nanoparticles conjugated by peptide-1 for glioblastoma chemotherapy and photothermal therapy

Increased the TMZ concentration in brain by poly(2-ethyl-2-oxazoline) conjugated temozolomide prodrug micelles for glioblastoma treatment

Biomimetic Polymer-Templated Copper Nanoparticles Stabilize a Temozolomide Intermediate for Chemotherapy Against Glioblastoma Multiforme.

Enhancement of Temozolomide Stability and Anticancer Efficacy by Loading in Monopalmitolein-Based Cubic Phase Nanoparticles

PLGA-based dual-loaded nanoformulation of DIM and TMZ - An advanced clinical strategy for brain cancer treatment in a combinatorial approach

Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies

Carboxymethylcellulose biofunctionalized ternary quantum dots for subcellular-targeted brain cancer nanotheranostics

Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation

Yeast cell membrane-camouflaged PLGA nanoparticle platform for enhanced cancer therapy

Fabrication of pH-responsive temozolomide (TMZ)-clacked tannic acid-altered zeolite imidazole nanoframeworks (ZIF-8) enhance anticancer activity and apoptosis induction in glioma cancer cells

Brain-targeting redox-sensitive micelles for codelivery of TMZ and β-lapachone for glioblastoma therapy

Glioma nanotherapy: Unleashing the synergy of dual-loaded DIM and TMZ